Investment firm Eight Roads said this week it launched a $250 million China-focused healthcare fund, looking to invest in therapeutics, healthcare services, healthcare information technology, digital health and medical technology companies.
The firm said that 40% of the new fund will be focused on therapeutics, and that a dedicated technology fund is also in the pipeline.
“Eight Roads has backed innovative China healthcare companies since 1995. The launch of this specialized fund reflects our confidence in the evolution of the China market and forms part of a strategy to more precisely target our healthcare and technology expertise. The Eight Roads network constitutes one of the largest venture and early growth platforms in the world. The China Healthcare Fund takes its place as part of this powerful global ecosystem supported by a single investor and a 108-person strong investment team across China, India, Japan, Europe and the US. This ecosystem lends us capacity and scale, setting up powerful efficiencies, deep domain expertise, and the ability to trace trends and understanding across geographies,” senior managing partner Daniel Auerbach said in a prepared statement.
Eight Roads said that it will invest in both existing companies and new ventures which aim to “tackle unmet market demand,” as well as intransigent health and delivery issues.
Earlier this week, investment firm OrbiMed said it closed its 3rd Asian-focused healthcare private equity fund, having raised approximately $551 million in capital commitments.
